Sigrima 420mg

Sigrima 420mg is a prescription medication used to treat certain types of breast cancer and stomach cancer. It is a monoclonal antibody that targets the HER2 protein, which is found on the surface of some cancer cells.

Composition:

• Sigrima 420mg: Pertuzumab 420mg/14ml Injection

Mechanism of Action:

Sigrima 420mg works by:

1. Binding to the HER2 protein on the surface of cancer cells, which can help to:
   • Prevent the growth and spread of cancer cells
   • Reduce the production of certain growth factors that can promote cancer growth
   • Enhance the effects of chemotherapy
2. Inhibiting the activity of the HER2 protein, which can help to:
   • Reduce the production of certain growth factors that can promote cancer growth
   • Inhibit the activation of certain signaling pathways that can promote cancer growth

Indications:

Sigrima 420mg is approved for the treatment of:

• HER2-positive breast cancer in combination with docetaxel chemotherapy
• HER2-positive gastric cancer in combination with cisplatin and fluorouracil chemotherapy

Dosage:

The recommended dosage of Sigrima 420mg is:

• 420mg as an intravenous injection every 3 weeks
• The recommended duration of treatment is until disease progression or unacceptable toxicity occurs

Side Effects:

Common side effects of Sigrima 420mg include:

1. Infusion reactions
2. Fatigue
3. Headache
4. Muscle pain
5. Nausea
6. Vomiting
7. Diarrhea
8. Abdominal pain
9. Fever
10. Chills

Recommendation:

Sigrima 420mg is recommended for patients with HER2-positive breast cancer or gastric cancer who have not responded to other treatments.

Important Note:

• Patients taking Sigrima 420mg should be closely monitored for signs of cardiac problems, such as heart failure or arrhythmias.
• Patients taking Sigrima 420mg should avoid taking medications that may interact with it, such as anticoagulants or medications that can increase the risk of bleeding.
• Pregnant or breastfeeding women should not use Sigrima 420mg, as it may harm the fetus or infant.
• Regular follow-up appointments with your healthcare provider are necessary to monitor the effectiveness of Sigrima 420mg and to detect any potential side effects or complications.

Special Precautions:

• Patients with a history of heart problems or liver disease should be closely monitored while taking Sigrima 420mg.
• Patients with a history of severe allergic reactions should be closely monitored while taking Sigrima 420mg.

Contraindications:

• Patients who are allergic to pertuzumab or any other component of Sigrima 420mg should not use it.
• Patients who are pregnant or breastfeeding should not use Sigrima 420mg.
• Patients with severe liver disease or severe kidney disease should not use Sigrima 420mg.